Before joining I-Mab, Dr. Dennis was Vice President of Lung Cancer Strategy and the Global Project Head for a novel, first-in-class ADC at Sanofi (NASDAQ: SNY). Prior to Sanofi, Dr. Dennis was Vice President of Lung Cancer Strategy and Global Clinical Lead at AstraZeneca (NASDAQ: AZN). In these roles, Dr. Dennis served as the disease strategy head for lung cancer and led the cross-functional development of key assets, including IMFINZI®. Prior to his pharmaceutical career, Dr. Dennis was a widely published professor of Oncology, Medicine, and Pharmacology at Johns Hopkins University. Dr. Dennis received his MS, MD, and PhD degrees from the New York University School of Medicine as part of the Medical Scientist Training Program. Dr. Dennis completed his residency in Internal Medicine and fellowship in Medical Oncology at Johns Hopkins. Dr. Dennis also spent 14 years as a translational researcher at the US National Cancer Institute, achieving tenure as a Senior Investigator. He is an elected member of the American Society for Clinical Investigation and has won several awards, including an NIH Merit Award.
Skelton先生作为一位具有深厚资本市场交易背景的财务策略专家，曾参与及主导的累计交易价值超过200亿美元。在加入天境之前曾在Truist Securities任职生物制药领域高级副总裁。Skelton先生在金融领域拥有包括在医疗保健投资银行和制药领域逾十年经验的丰富背景，他在Cantor Fitzgerald以及Amneal Pharmaceuticals就职期间曾担任金融顾问等角色，参与并主导了多个关键战略项目。
徐聰博士在2018年天境生物美國分公司成立之初加入公司。她帶領團隊建立了馬里蘭州研發中心。徐聰博士負責公司全球管線在美國的醫學/臨床研究、臨床運營、註冊事務、臨床標記物和專案管理。她的團隊與中國團隊緊密合作，共同推進全球臨床研究策略和實施。
在加入天境生物之前，徐聰博士是大塚製藥美國分公司臨床藥理副主管，負責過多個治療領域包括腫瘤及血液病的臨床1/2期試驗。徐聰博士獲得了美國印第安那大學醫學院臨床藥理學博士學位和中山大學醫學院學士學位。